139 related articles for article (PubMed ID: 25056818)
1. Limited efficacy of intratumoral IL-2 applied to large melanoma metastases.
Weide B; Eigentler TK; Elia G; Neri D; Garbe C
Cancer Immunol Immunother; 2014 Nov; 63(11):1231-2. PubMed ID: 25056818
[No Abstract] [Full Text] [Related]
2. Fast-growing in-transit melanoma metastasis after intratumoral interleukin-2.
Moreno-Ramírez D; Alés-Martínez M; Ferrándiz L
Cancer Immunol Immunother; 2014 Nov; 63(11):1229-30. PubMed ID: 25056817
[No Abstract] [Full Text] [Related]
3. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.
Weide B; Eigentler TK; Pflugfelder A; Leiter U; Meier F; Bauer J; Schmidt D; Radny P; Pföhler C; Garbe C
Cancer Immunol Immunother; 2011 Apr; 60(4):487-93. PubMed ID: 21174093
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
Kirkwood JM; Tarhini AA
J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
[No Abstract] [Full Text] [Related]
5. [Prognostic significance of DNA ploidy in disseminated malignant skin melanoma and the effectiveness of interleukin-2 (IL-2) treatment].
Novik AV; Novik BI; Moiseenko VM
Vopr Onkol; 2007; 53(2):164-9. PubMed ID: 17663169
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy and chemoimmunotherapy for metastatic malignant melanoma: review and recent advances.
Khayat D; Coeffic D
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():238-47. PubMed ID: 10895160
[No Abstract] [Full Text] [Related]
7. Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease.
Hassan S; Petrella TM; Zhang T; Kamel-Reid S; Nordio F; Baccarelli A; Sade S; Naert K; Habeeb AA; Ghazarian D; Wright FC
Ann Surg Oncol; 2015; 22(6):1950-8. PubMed ID: 25366584
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
Radny P; Caroli UM; Bauer J; Paul T; Schlegel C; Eigentler TK; Weide B; Schwarz M; Garbe C
Br J Cancer; 2003 Nov; 89(9):1620-6. PubMed ID: 14583759
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy, cytokines, and biochemotherapy for melanoma.
Eton O
Cancer Chemother Biol Response Modif; 2005; 22():739-48. PubMed ID: 16110637
[No Abstract] [Full Text] [Related]
10. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.
Ellebaek E; Engell-Noerregaard L; Iversen TZ; Froesig TM; Munir S; Hadrup SR; Andersen MH; Svane IM
Cancer Immunol Immunother; 2012 Oct; 61(10):1791-804. PubMed ID: 22426890
[TBL] [Abstract][Full Text] [Related]
11. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
Dutcher JP
Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
[No Abstract] [Full Text] [Related]
12. [Zelboraf. Longer term survival for advanced stage melanoma].
Sabourin G
Perspect Infirm; 2012; 9(5):64-5. PubMed ID: 22978138
[No Abstract] [Full Text] [Related]
13. Treating metastatic melanoma: further considerations.
Legha SS
Oncology (Williston Park); 2009 May; 23(6):500, 508. PubMed ID: 19544691
[No Abstract] [Full Text] [Related]
14. [In vitro drug sensitivity profiling in melanoma].
Ugurel S
J Dtsch Dermatol Ges; 2008 Jul; 6(7):611. PubMed ID: 18611186
[No Abstract] [Full Text] [Related]
15. What can we learn from phase II adjuvant trials in melanoma?
Keilholz U; Suciu S; Eggermont AM
Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
[No Abstract] [Full Text] [Related]
16. Nivolumab success in untreated metastatic melanoma.
Wilkinson E
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
[No Abstract] [Full Text] [Related]
17. Node positive melanoma--a positive note?
Kelly J; Kerin MJ
Surgeon; 2012 Apr; 10(2):63-4. PubMed ID: 22385525
[No Abstract] [Full Text] [Related]
18. [Adjuvant drug therapy of malignant melanoma. Current knowledge and multi-center studies in German-speaking countries].
Hauschild A; Volkenandt M; Garbe C
Dtsch Med Wochenschr; 2000 Oct; 125(42):1272-8. PubMed ID: 11098240
[No Abstract] [Full Text] [Related]
19. Inhibition of the growth of murine malignant melanoma by polyinosinic-polycytidylic acid.
Bart RS; Kopf AW; Silagi S
J Invest Dermatol; 1971 Jan; 56(1):33-8. PubMed ID: 5556497
[No Abstract] [Full Text] [Related]
20. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.
Marabondo S; Kaufman HL
Expert Opin Drug Saf; 2017 Dec; 16(12):1347-1357. PubMed ID: 28929820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]